Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI)
CUSIP: 320703408
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Shares outstanding
- 7,142,857
- Total 13F shares
- 448,323
- Share change
- +237,292
- Total reported value
- $524,682
- Price per share
- $1.17
- Number of holders
- 27
- Value change
- +$271,225
- Number of buys
- 15
- Number of sells
- 4
Quarterly Holders Quick Answers
What is CUSIP 320703408?
CUSIP 320703408 identifies CLDI - Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 320703408:
Top shareholders of CLDI - Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
412,800
|
$4,330,272 | — | 19 Oct 2022 | |
| Stephen Thesing |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
471,544
|
$848,779 | — | 12 Sep 2023 | |
| Boris Radoslavov Minev |
3/4/5
|
Interim Chief Medical Officer |
—
mixed-class rows
|
455,818
mixed-class rows
|
$764,024 | — | 17 Jun 2024 | |
| Thomas A. Vecchiolla |
3/4/5
|
Director |
—
mixed-class rows
|
781,459
mixed-class rows
|
$657,189 | — | 21 Dec 2023 | |
| Tony T. Kalajian |
3/4/5
|
Chief Acctg Officer, Int. CFO |
—
class O/S missing
|
278,790
|
$501,822 | — | 12 Sep 2023 | |
| Heehyoung Lee |
3/4/5
|
Director, Former Director |
—
class O/S missing
|
246,720
|
$444,096 | — | 10 Oct 2023 | |
| Lincoln Alternative Strategies LLC |
3/4/5
|
10%+ Owner |
6.6%
|
730,000
|
$430,700 | — | 20 Aug 2025 | |
| Wendy Pizarro Campbell |
3/4/5
|
Chief Admin. and Legal Officer |
—
mixed-class rows
|
222,374
mixed-class rows
|
$292,273 | — | 17 Jun 2024 | |
| Alfonso G. Zulueta |
3/4/5
|
Director |
—
class O/S missing
|
133,301
|
$239,942 | — | 21 Dec 2023 | |
| HighTower Advisors, LLC |
13F
|
Company |
1.2%
|
84,956
|
$129,133 | — | 30 Sep 2025 | |
| Allan Camaisa |
3/4/5
|
Director |
1.1%
|
76,952
|
$111,965 | -$1,237 | 12 Dec 2025 | |
| Scott Leftwich |
3/4/5
|
Director |
—
mixed-class rows
|
408,709
mixed-class rows
|
$86,511 | — | 21 Aug 2025 | |
| Belpointe Asset Management LLC |
13F
|
Company |
—
mixed-class rows
|
41,642
mixed-class rows
|
$63,296 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.49%
|
34,728
|
$52,787 | — | 30 Sep 2025 | |
| Amish Patel |
3/4/5
|
VP of Technical Operations |
—
class O/S missing
|
29,303
|
$52,745 | — | 12 Sep 2023 | |
| George K. Ng |
3/4/5
|
Director |
—
class O/S missing
|
28,092
|
$50,566 | — | 12 Sep 2023 | |
| James A. Schoeneck |
3/4/5
|
Director |
—
mixed-class rows
|
324,007
mixed-class rows
|
$49,862 | — | 21 Aug 2025 | |
| Alan R. Stewart |
3/4/5
|
Director |
—
mixed-class rows
|
166,054
mixed-class rows
|
$46,941 | — | 09 Jul 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.41%
|
29,595
|
$44,984 | — | 30 Sep 2025 | |
| David Sans |
3/4/5
|
Chief of Corporate Development |
—
class O/S missing
|
18,314
|
$32,965 | — | 12 Sep 2023 | |
| Warberg Asset Management LLC |
13F
|
Company |
0.26%
|
18,705
|
$28,432 | — | 30 Sep 2025 | |
| RS CRUM INC. |
13F
|
Company |
0.21%
|
15,256
|
$23,190 | — | 30 Sep 2025 | |
| Eric E. Poma |
3/4/5
|
Chief Executive Officer |
—
mixed-class rows
|
786,412
mixed-class rows
|
$14,750 | — | 03 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.04%
|
2,564
|
$3,897 | — | 30 Sep 2025 | |
| Finepoint Capital LP |
13F
|
Company |
0.01%
|
1,042
|
$1,584 | — | 30 Sep 2025 | |
| Apollo Management Holdings, L.P. |
13F
|
Company |
0.01%
|
1,042
|
$1,583 | — | 30 Sep 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.01%
|
1,042
|
$1,583 | — | 30 Sep 2025 | |
| Andrew C. Jackson |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
35,000
mixed-class rows
|
$1,475 | — | 03 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.01%
|
417
|
$1,000 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
387
|
$588 | — | 30 Sep 2025 | |
| BARRETT & COMPANY, INC. |
13F
|
Company |
0%
|
292
|
$444 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
—
mixed-class rows
|
400
mixed-class rows
|
$377 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
0%
|
125
|
$190 | — | 30 Sep 2025 | |
| Tradewinds Capital Management, LLC |
13F
|
Company |
0%
|
101
|
$154 | — | 30 Sep 2025 | |
| Reyes Financial Architecture, Inc. |
13F
|
Company |
0%
|
100
|
$152 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
46
|
$70 | — | 30 Sep 2025 | |
| CVA Family Office, LLC |
13F
|
Company |
0%
|
42
|
$64 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
30
|
$46 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
9
|
$14 | — | 30 Sep 2025 | |
| EVERMAY WEALTH MANAGEMENT LLC |
13F
|
Company |
0%
|
1
|
$2 | — | 30 Sep 2025 | |
| First Light Acquisition Group, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,931,852
|
— | — | 16 Jun 2023 | |
| George Peoples |
3/4/5
|
Director |
—
class O/S missing
|
137,078
|
— | — | 09 Jul 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
117,368
|
— | $0 | 30 Jun 2025 | |
| Antonio Fernandez Santidrian |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
35,000
|
— | — | 03 Sep 2025 |
Institutional Holders of Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI) as of Q4 2025
As of 31 Dec 2025,
Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
448,323 shares.
The largest 10 holders included
DRW Securities, LLC, HighTower Advisors, LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, FMR LLC, Virtu Financial LLC, RS CRUM INC., Belpointe Asset Management LLC, NORTHERN TRUST CORP, and JANE STREET GROUP, LLC.
This page lists
27
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
21
Q4 2025 holders
27
Holder diff
6
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.